Nathan Connell on Real-World Evidence: A Safe Switch to New rFVIIa Avoided Over $550K in Costs
Nathan Connell, Clinical Chief of Hematology at Brigham and Women’s Faulkner Hospital, shared on LinkedIn:
“New Research: Real-World Evidence on Recombinant Factor VIIa Substitution
I’m excited to share our team’s latest publication in Clinical and Applied Thrombosis/Hemostasis. We conducted a retrospective evaluation of our conversion from eptacog alfa (NovoSeven) to eptacog beta (Sevenfact) to assess both clinical safety and financial impact at Brigham and Women’s Hospital.
Key Findings:
- Safety: The transition to eptacog beta showed no adverse thrombotic events across the patient cohort.
- Efficacy: Effective management was maintained for indications including hemophilia bleeding and peri-procedural management.
- Impact: The medication use evaluation identified an estimated cost avoidance of $554,400 over 12 months.
This study supports the viability of therapeutic interchange for rFVIIa products, offering a pathway for other institutions to maintain high-quality care while optimizing costs.
Read the full open-access article here.”
Title: Real World Experience with use of Coagulation Factor VIIa at an Academic Medical Center
Authors: Alyssa R. George, Katelyn W. Sylvester, Dareen M. Kanaan, Prabashni Reddy, John R. Fanikos, Jean M. Connors, Nathan T. Connell

Explore more posts for deeper insights into hemostasis with Hemostasis Today.
-
Oct 5, 2026, 15:31Irma Bagdoniene: Multidisciplinary Management of High-Risk Familial Hypercholesterolaemia and CAD
-
Oct 5, 2026, 15:00Serena Williams and Pulmonary Embolism: From Personal Crisis to Lessons in Venous Thromboembolism
-
Oct 5, 2026, 14:55Marco Moscarelli: 3D Reconstruction Enhances Volumetric Assessment of Post-TAVI Thrombosis
-
Oct 5, 2026, 13:24Abdul Muqtadir Abbasi: Diagnostic Pearls for Evaluating Isolated Thrombocytopenia in Residents
-
Oct 5, 2026, 13:16Katerina Pavenski: Rethinking What ‘Normal’ Means for Iron Deficiency
-
Oct 5, 2026, 13:09Rick Matthews: Balancing Established VTE Partnerships with Innovative Interventional Technologies
-
Oct 5, 2026, 13:01Nawsherwan Mohammad: Recognizing TTP Before the ADAMTS13 Result Arrives
-
Oct 5, 2026, 12:51Bruno Pougault: The Hidden Challenges Behind Anti Xa Testing
-
Oct 5, 2026, 12:41Syed Huzaifa Khan: Rethinking CTRP12 as a Biomarker for In Stent Restenosis